These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 37301607)
1. Binding properties of selective inhibitors of P323L mutated RdRp of SARS-CoV-2: a combined molecular screening, docking and dynamics simulation study. Chinnamadhu A; Ramakrishnan J; Suresh S; Poomani K J Biomol Struct Dyn; 2024 May; 42(8):4283-4296. PubMed ID: 37301607 [TBL] [Abstract][Full Text] [Related]
2. Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type. Mohammad A; Al-Mulla F; Wei DQ; Abubaker J Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206274 [TBL] [Abstract][Full Text] [Related]
3. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study. Wakchaure PD; Ghosh S; Ganguly B J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493 [TBL] [Abstract][Full Text] [Related]
4. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir. Banerjee A; Kanwar M; Maiti S Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419 [TBL] [Abstract][Full Text] [Related]
5. Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective. Sonousi A; Mahran HA; Ibrahim IM; Ibrahim MN; Elfiky AA; Elshemey WM Pharmacol Rep; 2021 Dec; 73(6):1754-1764. PubMed ID: 34165771 [TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations. Showers WM; Leach SM; Kechris K; Strong M Infect Genet Evol; 2022 Jan; 97():105153. PubMed ID: 34801754 [TBL] [Abstract][Full Text] [Related]
7. Computational hunting of natural active compounds as an alternative for Remdesivir to target RNA-dependent polymerase. Saeed M; Saeed A; Alam MJ; Alreshidi M Cell Mol Biol (Noisy-le-grand); 2021 Jan; 67(1):45-49. PubMed ID: 34817369 [TBL] [Abstract][Full Text] [Related]
8. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase. Zhang L; Zhou R J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159 [TBL] [Abstract][Full Text] [Related]
9. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach. Dhankhar P; Dalal V; Kumar V J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. Jung LS; Gund TM; Narayan M Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784 [TBL] [Abstract][Full Text] [Related]
11. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. Tchesnokov EP; Gordon CJ; Woolner E; Kocinkova D; Perry JK; Feng JY; Porter DP; Götte M J Biol Chem; 2020 Nov; 295(47):16156-16165. PubMed ID: 32967965 [TBL] [Abstract][Full Text] [Related]
12. Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex. Olotu FA; Omolabi KF; Soliman MES Cell Biochem Biophys; 2021 Jun; 79(2):175-187. PubMed ID: 33792836 [TBL] [Abstract][Full Text] [Related]
14. Dynamics and binding affinity of nucleoside and non-nucleoside inhibitors with RdRp of SARS-CoV-2: a molecular screening, docking, and molecular dynamics simulation study. Chinnamadhu A; Ramakrishnan J; Suresh S; Ramadurai P; Poomani K J Biomol Struct Dyn; 2023 Dec; 41(20):10396-10410. PubMed ID: 36510678 [TBL] [Abstract][Full Text] [Related]
15. Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus. Tiwari V Int J Biol Macromol; 2021 Feb; 171():358-365. PubMed ID: 33421473 [TBL] [Abstract][Full Text] [Related]
16. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Jiang Y; Yin W; Xu HE Biochem Biophys Res Commun; 2021 Jan; 538():47-53. PubMed ID: 32943188 [TBL] [Abstract][Full Text] [Related]
17. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles. Rabie AM Chem Biol Interact; 2021 Jul; 343():109480. PubMed ID: 33887223 [TBL] [Abstract][Full Text] [Related]
18. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539 [TBL] [Abstract][Full Text] [Related]
19. Synthesis of Nucleoside-like Molecules from a Pyrolysis Product of Cellulose and Their Computational Prediction as Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors. Defant A; Dosi F; Innocenti N; Mancini I Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008944 [TBL] [Abstract][Full Text] [Related]
20. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]